Vanguard Group Inc Annovis Bio, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 466,277 shares of ANVS stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

466,277

Previous 380,255 22.62%

Holding current value

$1.27 Million

Previous $3.06 Million 23.47%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$4.37 - $9.87 $375,916 - $849,037	86,022 Added 22.62%	466,277 $2.35 Million
Q3 2024 Nov 13, 2024	BUY	$5.27 - $15.46 $99,608 - $292,209	18,901 Added 5.23%	380,255 $3.06 Million
Q2 2024 Aug 13, 2024	BUY	$4.82 - $18.01 $16,445 - $61,450	3,412 Added 0.95%	361,354 $2.08 Million
Q1 2024 May 10, 2024	BUY	$8.47 - $18.93 $174,380 - $389,730	20,588 Added 6.1%	357,942 $4.26 Million
Q4 2023 Feb 14, 2024	BUY	$5.55 - $19.62 $437,473 - $1.55 Million	78,824 Added 30.49%	337,354 $6.31 Million
Q3 2023 Nov 14, 2023	BUY	$9.37 - $14.12 $60,904 - $91,780	6,500 Added 2.58%	258,530 $2.45 Million
Q2 2023 Aug 14, 2023	BUY	$11.95 - $16.31 $113,035 - $154,276	9,459 Added 3.9%	252,030 $3.6 Million
Q4 2022 Feb 10, 2023	BUY	$10.99 - $13.8 $1,208 - $1,518	110 Added 0.05%	242,571 $3.26 Million
Q1 2022 May 13, 2022	BUY	$11.84 - $19.78 $157,543 - $263,192	13,306 Added 5.81%	242,461 $3.24 Million
Q4 2021 Feb 14, 2022	SELL	$17.58 - $37.67 $5,783 - $12,393	-329 Reduced 0.14%	229,155 $4.03 Million
Q3 2021 Nov 12, 2021	BUY	$30.95 - $120.97 $959 - $3,750	31 Added 0.01%	229,484 $7.29 Million
Q2 2021 Aug 13, 2021	BUY	$21.55 - $96.1 $4.94 Million - $22.1 Million	229,453 New	229,453 $19.6 Million

Others Institutions Holding ANVS

# of Institutions

Shares Held

1.37M

Call Options Held

364K

Put Options Held

494K

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $22.3M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Annovis Bio, Inc. Transaction History